{"id":"W3129286763","doi":"10.1158/1538-7445.sabcs20-ot-30-01","title":"Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Pembrolizumab; Medicine; Oncology; Olaparib; Internal medicine; Chemotherapy; Gemcitabine; Atezolizumab; PARP inhibitor; Carboplatin; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002342347,0.001669636,0.002459866,0.0003327343,0.0005047673,0.001525284,0.001077474,0.001986831,0.01243177],"category_scores_gemma":[0.001502831,0.0007531145,0.00186302,0.0004276359,0.001258762,0.001355491,0.0004464358,0.005217046,0.002141966],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001192846,"about_ca_system_score_gemma":0.001880221,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001362091,"about_ca_topic_score_gemma":0.003302426,"domain_scores_codex":[0.9994023,0.0003100721,0.00003393375,0.0001151574,0.00004608617,0.00009245991],"domain_scores_gemma":[0.9988688,0.0002115987,0.0002512262,0.00007632189,0.00008765674,0.0005043492],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9628892,0.01520728,0.0004416787,0.0007122108,0.0008003245,0.00003492065,0.00004223039,0.000243392,0.004638629,0.0001204189,0.001879441,0.01299033],"study_design_scores_gemma":[0.9322028,0.06502683,0.001014628,0.00002961899,0.0003321965,0.00002754868,0.00001807964,0.0002622888,0.0002823116,0.0001030641,0.000689782,0.00001094592],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9638768,0.006993745,0.001271182,0.002217762,0.001376636,0.01464307,0.004432287,0.0003662257,0.004822311],"genre_scores_gemma":[0.9666232,0.003575193,0.00314746,0.003253802,0.0006250872,0.01186569,0.003520488,0.0000764217,0.007312594],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01243177,"threshold_uncertainty_score":0.04158843,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07989167611688573,"score_gpt":0.4142837333848557,"score_spread":0.33439205726797,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}